Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19.
<h4>Background and objectives</h4>In 2020, the world was profoundly affected by the spread of SARS-CoV-2, a novel coronavirus first identified in December 2019, that was the causative agent of coronavirus disease 2019 (Covid-19), a severe respiratory disease classified as a pandemic by t...
Main Authors: | Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0279022 |
Similar Items
-
Comparison of Monoclonal Antibody Cocktail (Casirivimab-Imdevimab) Treatment With Remdesivir and Favipiravir in Mild to Moderate COVID-19 Infection: A Retrospective Study
by: Rahul Rajaram Tambe, et al.
Published: (2023-02-01) -
Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
by: Gaetano Cicchitto, et al.
Published: (2022-03-01) -
Warm autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis/macrophage activation syndrome occurring after COVID19 infection and administration of Casirivimab + Imdevimab (COVID19 monoclonal antibody)
by: Andrew W. Swartz, et al.
Published: (2024-02-01) -
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
by: Dateng Li, et al.
Published: (2023-08-01) -
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
by: Nicola Schiano Moriello, et al.
Published: (2023-02-01)